HLB (028300) Q3 2024 earnings summary

Executive summary

• Operates in three main segments: healthcare (diagnostics, medical devices), bio (oncology drug development), and shipbuilding (specialty vessels, pipes).

• Recent focus on expanding bio and healthcare, with shipbuilding spun off in May 2023.

• Key subsidiaries include Elevar Therapeutics (oncology drugs) and Immunomic Therapeutics (immunotherapy platforms).

Financial highlights

• 2024 Q3 consolidated revenue: ₩42.9 billion, flat year-over-year.

• Operating loss: ₩92.8 billion; net loss: ₩78.3 billion, both improved from prior year.

• R&D expenses: ₩28.9 billion, 67.3% of sales.

• Cash and equivalents at Q3-end: ₩89.7 billion.

Outlook and guidance

• Focus on FDA approval and commercialization of Rivoceranib (liver cancer drug) in the US.

• Plans to expand diagnostic and consumer healthcare product lines, with new launches and aggressive marketing in 2024.

• Ongoing investment in pipeline expansion and global clinical trials.